N. Alrabadi, N. Gibson, K. Curless, L. Cheng, M. Kuhar et al., Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma, Modern Pathology, vol.32, pp.330-337, 2019.

R. N. Amaria, P. A. Prieto, M. T. Tetzlaff, A. Reuben, M. C. Andrews et al., Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial, The Lancet Oncology, vol.19, pp.181-193, 2018.

C. M. Balch, J. E. Gershenwald, S. Soong, J. F. Thompson, M. B. Atkins et al., Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, pp.6199-6206, 2009.

A. D. Ballantyne, G. , and K. P. , Dabrafenib: First Global Approval, Drugs, vol.73, pp.1367-1376, 2013.

B. C. Bastian, The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia, Annu Rev Pathol, vol.9, pp.239-271, 2014.

B. C. Bastian, P. E. Leboit, and D. Pinkel, Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features, Am. J. Pathol, vol.157, pp.967-972, 2000.

C. Beadling, E. Jacobson-dunlop, F. S. Hodi, C. Le, A. Warrick et al., KIT Gene Mutations and Copy Number in Melanoma Subtypes, Clinical Cancer Research, vol.14, pp.6821-6828, 2008.

E. Birkeland, S. Zhang, D. Poduval, J. Geisler, S. Nakken et al., Patterns of genomic evolution in advanced melanoma, Nature Communications, vol.9, 2018.

C. Bisschop, A. Ter-elst, L. J. Bosman, I. Platteel, M. Jalving et al., Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform, Melanoma Research, vol.28, pp.96-104, 2018.

T. Botton, I. Yeh, T. Nelson, S. S. Vemula, A. Sparatta et al., Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy, Pigment Cell Melanoma Res, vol.26, pp.845-851, 2013.

A. Bourhis, G. Le-flahec, and A. Uguen, Decalcification can cause the failure of BRAF molecular analyses and anti-BRAFV600E VE1 immunohistochemistry, Pathology International, vol.69, pp.219-223, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02262344

L. Boursault, V. Haddad, B. Vergier, D. Cappellen, S. Verdon et al., Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing, PLoS ONE, vol.8, p.70826, 2013.

J. R. Bradish, J. D. Richey, K. M. Post, K. Meehan, J. D. Sen et al., Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy, Modern Pathology, vol.28, pp.480-486, 2015.

M. S. Brose, P. Volpe, M. Feldman, M. Kumar, I. Rishi et al., BRAF and RAS mutations in human lung cancer and melanoma, Cancer Res, vol.62, pp.6997-7000, 2002.

K. J. Busam, C. Hedvat, M. Pulitzer, A. Von-deimling, and A. A. Jungbluth, , 2013.

, Immunohistochemical Analysis of BRAFV600E Expression of Primary and Metastatic Melanoma and Comparison With Mutation Status and Melanocyte Differentiation Antigens of Metastatic Lesions, The American Journal of Surgical Pathology, vol.37, pp.413-420

K. J. Busam, K. N. Shah, P. Gerami, T. Sitzman, A. A. Jungbluth et al., , 2017.

, Reduced H3K27me3 Expression Is Common in Nodular Melanomas of Childhood Associated With Congenital Melanocytic Nevi But Not in Proliferative Nodules, The American Journal of Surgical Pathology, vol.41, pp.396-404

D. Capper, M. Preusser, A. Habel, F. Sahm, U. Ackermann et al., Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody, Acta Neuropathologica, vol.122, pp.11-19, 2011.

Q. Chen, C. Xia, Y. Deng, M. Wang, P. Luo et al., Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients, Tumor Biology, vol.35, pp.5727-5733, 2014.

W. H. Clark, D. E. Elder, and M. Van-horn, The biologic forms of malignant melanoma, Human Pathology, vol.17, pp.443-450, 1986.

J. N. Cohen, N. M. Joseph, J. P. North, C. Onodera, A. Zembowicz et al., , 2017.

. Prkca-genes, Genomic Analysis of Pigmented Epithelioid Melanocytomas Reveals Recurrent Alterations in PRKAR1A, and, vol.41, pp.1333-1346

E. Colomba, Z. Hélias-rodzewicz, A. Von-deimling, C. Marin, N. Terrones et al., Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing, J Mol Diagn, vol.15, pp.94-100, 2013.

M. Colombino, A. Lissia, M. Capone, V. De-giorgi, D. Massi et al., Heterogeneous distribution of BRAF/NRAS 53 mutations among Italian patients with advanced melanoma, Journal of Translational Medicine, vol.11, p.202, 2013.

J. A. Curtin, J. Fridlyand, T. Kageshita, H. N. Patel, K. J. Busam et al., Distinct Sets of Genetic Alterations in Melanoma, New England Journal of Medicine, vol.353, pp.2135-2147, 2005.

J. A. Curtin, K. Busam, D. Pinkel, and B. C. Bastian, Somatic Activation of KIT in Distinct Subtypes of Melanoma, Journal of Clinical Oncology, vol.24, pp.4340-4346, 2006.

J. Dai, M. T. Tetzlaff, L. M. Schuchter, D. E. Elder, and R. Elenitsas, Histopathologic and mutational analysis of a case of blue nevus-like melanoma: Analysis of a case of BNLM, Journal of Cutaneous Pathology, vol.43, pp.776-780, 2016.

H. Davies, G. R. Bignell, C. Cox, P. Stephens, S. Edkins et al., Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-954, 2002.

E. L. Van-dijk, Y. Jaszczyszyn, and C. Thermes, Library preparation methods for nextgeneration sequencing: Tone down the bias, Experimental Cell Research, vol.322, pp.12-20, 2014.

E. Edlundh-rose, S. Egyházi, K. Omholt, E. Månsson-brahme, A. Platz et al., NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing, Melanoma Res, vol.16, pp.471-478, 2006.

L. Ehsani, C. Cohen, K. E. Fisher, and M. T. Siddiqui, BRAF Mutations in Metastatic Malignant Melanoma: Comparison of Molecular Analysis and Immunohistochemical Expression, Applied Immunohistochemistry & Molecular Morphology, vol.22, pp.648-651, 2014.

H. Eriksson, A. Zebary, I. Vassilaki, K. Omholt, M. Ghaderi et al., BRAF V600E Protein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases, JAMA Dermatology, vol.151, p.410, 2015.

H. C. Etchevers, C. Rose, B. Kahle, H. Vorbringer, F. Fina et al., Giant congenital melanocytic nevus with vascular malformation and epidermal cysts associated with a somatic activating mutation in BRAF, Pigment Cell & Melanoma Research, vol.31, pp.437-441, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01613153

M. Etienne, F. Oca, D. Prunier-mirebeau, A. Croué, M. et al., , 2018.

. L'immunohistochimie, clone VE1) est une méthode économique, spécifique et sensible pour détecter la présence d'une mutation BRAFV600E dans le mélanome, Annales de Dermatologie et de Vénéréologie, vol.145, pp.159-165

M. B. Faries, J. F. Thompson, A. J. Cochran, R. H. Andtbacka, N. Mozzillo et al., Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma, New England Journal of Medicine, vol.376, pp.2211-54, 2017.

J. K. Feller, S. Yang, and M. Mahalingam, Immunohistochemistry with a mutationspecific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma, Modern Pathology, vol.26, pp.414-420, 2013.

K. E. Fisher, C. Cohen, M. T. Siddiqui, J. F. Palma, E. H. Lipford et al., , 2014.

, Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays, Hum. Pathol, vol.45, pp.2281-2293

S. J. Furney, M. Pedersen, D. Gentien, A. G. Dumont, A. Rapinat et al., SF3B1 mutations are associated with alternative splicing in uveal melanoma, Cancer Discov, vol.3, pp.1122-1129, 2013.

D. Govender and R. Chetty, Gene of the month: BRAF, J. Clin. Pathol, vol.65, pp.986-988, 2012.

K. G. Griewank, H. Müller, L. A. Jackett, M. Emberger, I. Möller et al., SF3B1 and BAP1 mutations in blue nevus-like melanoma, Mod. Pathol, vol.30, pp.928-939, 2017.

T. M. Grzywa, W. Paskal, and P. K. W?odarski, Intratumor and Intertumor Heterogeneity in Melanoma, Translational Oncology, vol.10, pp.956-975, 2017.

J. W. Harbour, M. D. Onken, E. D. Roberson, S. Duan, L. Cao et al., Frequent mutation of BAP1 in metastasizing uveal melanomas, Science, vol.330, pp.1410-1413, 2010.

A. Harlé, J. Salleron, C. Franczak, C. Dubois, P. Filhine-tressarieu et al., Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma, PLOS ONE, vol.11, 2016.

G. Hatzivassiliou, K. Song, I. Yen, B. J. Brandhuber, D. J. Anderson et al., RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, vol.464, pp.431-435, 2010.

L. Heinzerling, M. Baiter, S. Kühnapfel, G. Schuler, P. Keikavoussi et al., Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations, British Journal of Cancer, vol.109, pp.2833-2841, 2013.

V. Hofman, M. Ilie, E. Long-mira, D. Giacchero, C. Butori et al., Usefulness of Immunocytochemistry for the Detection of the BRAFV600E Mutation in Circulating Tumor Cells from Metastatic Melanoma Patients, Journal of Investigative Dermatology, vol.133, pp.1378-1381, 2013.

W. Huang, T. Kuo, C. Wu, H. Cheng, C. Hsieh et al., A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan: Detecting BRAF mutation in melanoma, Asia-Pacific Journal of Clinical Oncology, vol.12, pp.403-408, 2016.

M. A. Ihle, J. Fassunke, K. König, I. Grünewald, M. Schlaak et al., Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations, BMC Cancer, vol.14, p.13, 2014.

K. J. Jabbar, R. Luthra, K. P. Patel, R. R. Singh, R. Goswami et al., Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry, The American Journal of Surgical Pathology, vol.39, pp.454-461, 2015.

P. Johansson, L. G. Aoude, K. Wadt, W. J. Glasson, S. K. Warrier et al., Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4, Oncotarget, vol.7, 2016.

P. Just, A. Audebourg, E. Pasmant, E. Clauser, A. Carlotti et al., Immunohistochemistry versus nextgeneration sequencing for the routine detection of BRAF V600E mutation in melanomas, Human Pathology, vol.45, pp.1983-1984, 2014.

H. Kakavand, E. Walker, T. Lum, J. S. Wilmott, C. I. Selinger et al., BRAF V600E and NRAS Q61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting, Histopathology, vol.69, pp.680-686, 2016.

K. Kemper, O. Krijgsman, X. Kong, P. Cornelissen-steijger, A. Shahrabi et al., BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts, Cell Reports, vol.16, pp.263-277, 2016.

G. Kim, A. E. Mckee, Y. Ning, M. Hazarika, M. Theoret et al., FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation, Clin. Cancer Res, vol.20, pp.4994-5000, 2014.

V. A. Kinsler, A. C. Thomas, M. Ishida, N. W. Bulstrode, S. Loughlin et al., Multiple Congenital Melanocytic Nevi and Neurocutaneous Melanosis Are Caused by Postzygotic Mutations in Codon 61 of NRAS, Journal of Investigative Dermatology, vol.133, pp.2229-2236, 2013.

V. A. Kinsler, P. O'hare, N. Bulstrode, J. E. Calonje, W. K. Chong et al., Melanoma in congenital melanocytic naevi, British Journal of Dermatology, vol.176, pp.1131-1143, 2017.

A. Knol, M. Pandolfino, A. Vallée, F. Nguyen, V. Lella et al., Comparative analysis of BRAF , NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma, Experimental Dermatology, vol.24, pp.70-73, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01818897

S. Krengel, A. Hauschild, and T. Schafer, Melanoma risk in congenital melanocytic naevi: a systematic review, British Journal of Dermatology, vol.155, pp.1-8, 2006.

J. Lade-keller, L. S. Kristensen, R. Riber-hansen, P. Guldberg, L. L. Hansen et al., A role for immunohistochemical detection of BRAF V600E prior to BRAFinhibitor treatment of malignant melanoma, Journal of Clinical Pathology, vol.66, pp.723-725, 2013.

S. Lee, J. E. Kim, H. S. Jang, K. H. Park, B. H. Oh et al., Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions, Cancer Research and Treatment, vol.50, pp.1378-1387, 2018.

A. Lièvre and P. Laurent-puig, La voie de signalisation RAS/MAPK. Cancéro Digest II, 2010.

H. Liu, Z. Li, Y. Wang, Q. Feng, L. Si et al., , 2014.

, Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1, Pathol. Int, vol.64, pp.601-606

M. C. Lo, A. Paterson, J. Maraka, R. Clark, J. Goodwill et al., A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma, British Journal of Cancer, vol.115, pp.223-227, 2016.

I. M. Løes, H. Immervoll, J. Angelsen, A. Horn, J. Geisler et al., Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens, Tumor Biology, vol.36, pp.1003-1013, 2015.

G. V. Long, A. M. Menzies, A. M. Nagrial, L. E. Haydu, A. L. Hamilton et al., Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma, J. Clin. Oncol, vol.29, pp.1239-1246, 2011.

G. V. Long, J. S. Wilmott, D. Capper, M. Preusser, Y. E. Zhang et al., Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma, Am. J. Surg. Pathol, vol.37, pp.61-65, 2013.

G. V. Long, A. Hauschild, M. Santinami, V. Atkinson, M. Mandalà et al., , 2017.

I. Stage, . Braf--mutated, and . Melanoma, New England Journal of Medicine, vol.377, pp.1813-1823

J. J. Lyu, Y. Y. Kong, X. Cai, X. X. Shen, Y. W. Lu et al., Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma, 2017.

, Zhonghua Bing Li Xue Za Zhi, vol.46, pp.548-552

M. Maio, K. Lewis, L. Demidov, M. Mandalà, I. Bondarenko et al., Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebocontrolled, multicentre, The Lancet Oncology, vol.19, pp.510-520, 2018.

L. Manfredi, N. Meyer, E. Tournier, D. Grand, E. Uro-coste et al., Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma, Acta Dermato Venereologica, vol.96, pp.630-634, 2016.

P. Marino, R. Touzani, I. Borget, E. Rouleau, I. Durand-zaleski et al., Coût du séquençage NGS à visée diagnostique en génétique somatique et constitutionnelle : estimations issues de 15 laboratoires français de génétique moléculaire des cancers, vol.65, pp.83-84, 2017.

M. Martin, L. Maßhöfer, P. Temming, S. Rahmann, C. Metz et al., Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3, Nature Genetics, vol.45, pp.933-936, 2013.

G. Massi and P. E. Leboit, Histological Diagnosis of Nevi and Melanoma, 2014.

I. Möller, R. Murali, H. Müller, T. Wiesner, L. A. Jackett et al., Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi, Modern Pathology, vol.30, pp.350-356, 2017.

K. R. Moon, Y. D. Choi, J. M. Kim, S. Jin, M. Shin et al., Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features, Journal of Investigative Dermatology, vol.138, pp.933-945, 2018.

L. B. Nielsen, N. Dabrosin, K. Sloth, M. L. Bønnelykke-behrndtz, T. Steiniche et al., Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases, Histopathology, vol.72, pp.814-825, 2018.

G. Orchard, K. Wojcik, W. Rickaby, B. Martin, K. Semkova et al., Immunohistochemical detection of V600E BRAF mutation is a useful primary screening tool for malignant melanoma, British Journal of Biomedical Science, vol.76, pp.77-82, 2019.

O. Pavlova, S. Fraitag, and D. Hohl, 5-Hydroxymethylcytosine Expression in 58, 2016.

, Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma, Journal of Investigative Dermatology, vol.136, pp.2453-2461

M. V. Pearlstein, D. C. Zedek, D. W. Ollila, A. Treece, M. L. Gulley et al., Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma: VE1 immunostain for BRAF V600E mutant melanoma, Journal of Cutaneous Pathology, vol.41, pp.724-732, 2014.

P. M. Pollock, U. L. Harper, K. S. Hansen, L. M. Yudt, M. Stark et al., High frequency of BRAF mutations in nevi, Nature Genetics, vol.33, pp.19-20, 2003.

T. Qiu, H. Lu, L. Guo, W. Huang, Y. Ling et al., , 2015.

S. S. Raghavan, S. Peternel, T. W. Mully, J. P. North, L. B. Pincus et al., Spitz melanoma is a distinct subset of spitzoid melanoma, Modern Pathology, 2020.

E. Riveiro-falkenbach, C. A. Villanueva, M. C. Garrido, Y. Ruano, R. M. García-martín et al., Intra-and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors, J. Invest. Dermatol, vol.135, pp.3078-3085, 2015.

C. A. Routhier, M. C. Mochel, K. Lynch, D. Dias-santagata, D. N. Louis et al., Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas, Human Pathology, vol.44, pp.2563-2570, 2013.

J. C. Rubinstein, M. Sznol, A. C. Pavlick, S. Ariyan, E. Cheng et al., Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032, J Transl Med, vol.8, p.67, 2010.

M. Saint-jean, G. Quéreux, J. Nguyen, L. Peuvrel, A. Brocard et al., Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy, Journal of Investigative Dermatology, vol.134, pp.1468-1470, 2014.

E. Sener, P. Yildirim, A. Tan, O. Gokoz, and G. G. Tezel, Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma, Pathology -Research and Practice, vol.213, pp.522-530, 2017.

A. H. Shain and B. C. Bastian, From melanocytes to melanomas, Nat. Rev. Cancer, vol.16, pp.345-358, 2016.

D. Shitara, M. M. Nascimento, S. Puig, S. Yamada, M. M. Enokihara et al., Nevus-associated melanomas: clinicopathologic features, Am. J. Clin. Pathol, vol.142, pp.485-491, 2014.

A. D. Singh, M. E. Turell, and A. K. Topham, Uveal Melanoma: Trends in Incidence, Treatment, and Survival, Ophthalmology, vol.118, pp.1881-1885, 2011.

A. Skorokhod, D. Capper, A. Von-deimling, A. Enk, and P. Helmbold, Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1, Journal of the American Academy of Dermatology, vol.67, pp.488-491, 2012.

D. Solit and N. Rosen, Oncogenic RAF: a brief history of time, Pigment Cell Melanoma Res, vol.23, pp.760-762, 2010.

A. Thiel, M. Moza, S. Kytölä, A. Orpana, T. Jahkola et al., Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma, Human Pathology, vol.46, pp.169-175, 2015.

A. Valachis and G. J. Ullenhag, Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis, European Journal of Cancer, vol.81, pp.106-115, 2017.

A. Vallée, M. Denis-musquer, G. Herbreteau, S. Théoleyre, C. Bossard et al., Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay, PLoS ONE, vol.14, 2019.

C. D. Van-raamsdonk, V. Bezrookove, G. Green, J. Bauer, L. Gaugler et al., Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi, Nature, vol.457, pp.599-602, 2009.

C. D. Van-raamsdonk, V. Bezrookove, G. Green, J. Bauer, L. Gaugler et al., Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi, Nature, vol.457, pp.599-602, 2009.

C. D. Van-raamsdonk, K. G. Griewank, M. B. Crosby, M. C. Garrido, S. Vemula et al., Mutations in GNA11 in Uveal Melanoma, vol.363, pp.2191-2199, 2010.

C. D. Van-raamsdonk, K. G. Griewank, M. B. Crosby, M. C. Garrido, S. Vemula et al., Mutations in GNA11 in Uveal Melanoma, vol.363, pp.2191-2199, 2010.

Y. Wang, Y. Zhao, and S. Ma, Racial differences in six major subtypes of melanoma: descriptive epidemiology, BMC Cancer, vol.16, p.691, 2016.

T. Wiesner, R. Murali, I. Fried, L. Cerroni, K. Busam et al., , 2012.

, A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of 60 BAP1 Expression, The American Journal of Surgical Pathology, vol.36, pp.818-830

T. Wiesner, J. He, R. Yelensky, R. Esteve-puig, T. Botton et al., Kinase fusions are frequent in Spitz tumours and spitzoid melanomas, Nat Commun, vol.5, p.3116, 2014.

T. K. Wojdacz and A. Dobrovic, Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation, Nucleic Acids Research, vol.35, pp.41-41, 2007.

M. Yancovitz, A. Litterman, J. Yoon, E. Ng, R. L. Shapiro et al., Intra-and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma, PLoS ONE, vol.7, 2012.

I. Yeh, A. Von-deimling, and B. C. Bastian, Clonal BRAF Mutations in Melanocytic Nevi and Initiating Role of BRAF in Melanocytic Neoplasia, JNCI: Journal of the National Cancer Institute, vol.105, pp.917-919, 2013.

I. Yeh, T. W. Mully, T. Wiesner, S. S. Vemula, S. A. Mirza et al., Ambiguous Melanocytic Tumors With Loss of 3p21, The American Journal of Surgical Pathology, vol.38, pp.1088-1095, 2014.

I. Yeh, T. Botton, E. Talevich, A. H. Shain, A. J. Sparatta et al., Activating MET kinase rearrangements in melanoma and Spitz tumours, Nat Commun, vol.6, p.7174, 2015.

I. Yeh, M. K. Tee, T. Botton, A. H. Shain, A. J. Sparatta et al., NTRK3 kinase fusions in Spitz tumours, J. Pathol, vol.240, pp.282-290, 2016.

I. Yeh, U. E. Lang, E. Durieux, M. K. Tee, A. Jorapur et al., Combined activation of MAP kinase pathway and ?catenin signaling cause deep penetrating nevi, Nature Communications, vol.8, 2017.